FEED the BULL

Welcome to Feed the Bull - A home for investment information and interaction.

Tag: AVANIR Pharmaceuticals

Sort
E.g., 2013-05-20
E.g., 2013-05-20
Enter a comma separated list of user names.

Avalon Holdings Corporation (AMEX:AWX) released financial results for the second quarter of 2010. Net operating revenues in the second quarter of 2010 were $12.1 million compared with $8.4 million in the second quarter of 2009. For the first six months of 2010, net operating revenues increased to $20.4 million compared with $17.2 million for the first six months of 2009.

Windstream Corporation (NASDAQ:WIN) previously announced that it would buy Hosted Solutions LLC for $310 million, using the purchase to broaden its offerings in its business services and broadband segments. The cash deal is subject to regulatory approval, but the companies say they expect the transaction to close in the fourth quarter.

American Video Teleconferencing Corp. (Pink Sheets:AVOT) is pleased to announce that it has hired a French speaking geologist to search the archives of the Quebec Department of Mines for Rare Earths showings not on a current computer file. American Video believes the rare earths industry is where it wants to maintain a very strong focus and is looking to expand its holdings.

GreenHouse Holdings, Inc. (OTCQB:GRHU) previously announced the signing of multiple contract awards for its Life Protection (LPI) Governmental Services Division, totaling $6 million. The recently acquired LPI subsidiary provides innovative training, support, design and construction of facilities and services to meet the needs of the U. S. Government, military, and law enforcement agencies.

AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.

AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) announced that the U.S. Food and Drug Administration (FDA) has approved NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) capsules, as the first treatment for pseudobulbar affect.

AVANIR Pharmaceuticals, Inc. (Nasdaq:AVNR) today announced a management conference call to discuss the FDA approval of NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate) by the U.S. Food and Drug Administration (FDA). The call was earlier today, Monday November 1, 2010 at 5:15 a.m. Pacific time / 8:15 a.m. Eastern time.

Pages

ADVERTISE WITH US